NCIt definition : An orally bioavailable inhibitor of the serine/threonine kinase, transforming growth
factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase
5 (ALK5), with potential antineoplastic activity. Upon oral administration, vactosertib
inhibits the activity of TGFBR1 and prevents TGF-beta/TGFBR1-mediated signaling. This
suppresses tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1, which is overexpressed
in a variety of tumor cell types, plays a key role in tumor cell proliferation. Expression
of TGF-beta promotes tumor cell proliferation, enhances the migration of tumor cells
and suppresses the response of the host immune system to tumor cells.;
UNII : 6T4O391P5Y;
InChIKey : FJCDSQATIJKQKA-UHFFFAOYSA-N;
CAS number : 1352608-82-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1352608-82-2
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;